Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
$331.80M
Dr. João Siffert M.D.
56.00
Carlsbad, CA
Mar 26, 2021
-6.51
$-0.90
7.15
41.42
-6,029.71%
-6.46
-0.06
1.25
389.86
41.42
-18.74%
-18.48%
Similar stocks (10)
Cullinan Oncology, Inc.
CGEM
Erasca, Inc.
ERAS
Stoke Therapeutics, Inc.
STOK
C4 Therapeutics, Inc.
CCCC
Monte Rosa Therapeutics, Inc.
GLUE
ALX Oncology Holdings Inc.
ALXO
Werewolf Therapeutics, Inc.
HOWL
AlloVir, Inc.
ALVR
Ikena Oncology, Inc.
IKNA
Aadi Bioscience, Inc.
AADI
ETF Exposure (23)
iShares Micro-Cap ETF
IWC
0.03965%
iShares Russell 2000 Value ETF
IWN
0.0113%
Vanguard Russell 2000 Index Fund
VTWO
0.01%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
iShares Russell 2000 ETF
IWM
0.00578%
ProShares Ultra Russell2000
UWM
0.00219066412539883%
Schwab U.S. Small-Cap ETF
SCHA
0.0020750672%
ProShares UltraPro Russell2000
URTY
0.001079767859299821%
ProShares Hedge Replication ETF
HDG
9.131619400824452e-4%
Dimensional US Sustainability Core 1 ETF
DFSU
4.5145e-4%
Dimensional U.S. Targeted Value ETF
DFAT
3.7413e-4%
iShares Russell 3000 ETF
IWV
2.9e-4%
Dimensional US Core Equity Market ETF
DFAU
2.8479e-4%
Dimensional U.S. Equity ETF
DFUS
1.0972e-4%
Fidelity Nasdaq Composite Index ETF
ONEQ
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (10)
Cullinan Oncology, Inc.
CGEM
Erasca, Inc.
ERAS
Stoke Therapeutics, Inc.
STOK
C4 Therapeutics, Inc.
CCCC
Monte Rosa Therapeutics, Inc.
GLUE
ALX Oncology Holdings Inc.
ALXO
Werewolf Therapeutics, Inc.
HOWL
AlloVir, Inc.
ALVR
Ikena Oncology, Inc.
IKNA
Aadi Bioscience, Inc.
AADI
ETF Exposure (23)
iShares Micro-Cap ETF
IWC
0.03965%
iShares Russell 2000 Value ETF
IWN
0.0113%
Vanguard Russell 2000 Index Fund
VTWO
0.01%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
iShares Russell 2000 ETF
IWM
0.00578%
ProShares Ultra Russell2000
UWM
0.00219066412539883%
Schwab U.S. Small-Cap ETF
SCHA
0.0020750672%
ProShares UltraPro Russell2000
URTY
0.001079767859299821%
ProShares Hedge Replication ETF
HDG
9.131619400824452e-4%
Dimensional US Sustainability Core 1 ETF
DFSU
4.5145e-4%
Dimensional U.S. Targeted Value ETF
DFAT
3.7413e-4%
iShares Russell 3000 ETF
IWV
2.9e-4%
Dimensional US Core Equity Market ETF
DFAU
2.8479e-4%
Dimensional U.S. Equity ETF
DFUS
1.0972e-4%
Fidelity Nasdaq Composite Index ETF
ONEQ
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%